Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors

Haematologica

Volumn 100, Issue 8, 2015, Pages

  Thijssen, Rachel ^a   Slinger, Erik ^a   Weller, Katinka ^a   Geest, Christian R ^a   Beaumont, Tim ^b   Van Oers, Marinus H J ^a,c   Kater, Arnon P ^a,c   Eldering, Eric ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AIMM Therapeutics   (Netherlands)

^c Lymphoma and Myeloma Center Amsterdam LYMMCARE   (Netherlands)

Author keywords

ABT 199; CD20 antibodies; Chronic lymphocytic leukemia; Kinase inhibitors; Resistance

Indexed keywords

CD20 ANTIBODY; DASATINIB; IBRUTINIB; IDELALISIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; VENETOCLAX; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

APOPTOSIS; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; FLUORESCENCE MICROSCOPY; HUMAN; IN VITRO STUDY; LETTER; LYMPH NODE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM;

ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RITUXIMAB; SULFONAMIDES; TUMOR MICROENVIRONMENT;

EID: 84938596484     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.124560     Document Type: Letter

References (15)

1. Ten Hacken E, Burger JA. Molecular pathways: Targeting the microenvironment in chronic lymphocytic leukemia: focus on the B-cell receptor. Clin Cancer Res. 2014;(20):548-556.
2. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocitic leukemia cells correlates with survival capacity. Blood. 2007;(109):1660-1668.
3. Tromp JM, Tonino SH, Elias JA, et al. Dichotomy in NF-kB signaling and chemoresistance in immunoglobulin variable heavy-chainmutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene. 2010;(29):5071-5082.
4. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;(19):202-208.
5. Seymour JF, Davids MS, Pagel JM, et al. Updated results of a phase I first-in-human study of the Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory R/R chronic lymphocytic leukemia (CLL). J Clin Oncol. 2013;31(suppl; abstr 7018).
6. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;(123):3390-3397.
7. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; (369):32-42.
8. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood. 2010;(115):4393-4402.
9. Pascutti MF, Jak M, Tromp JM, et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013;(122):3010-3019.
10. Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009; (113):4403-4413.
11. Tromp JM, Geest CR, Breij EC, et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res. 2012;(18):487-498.
12. Jak M, van Bochove GG, van Lier RA, Eldering E, van Oers MH. CD40 stimulation sensitizes CLL cells to rituximab-induced cell death. Leukemia. 2011;(25):968-978.
13. Jak M, van Bochove GG, Reits EA, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood. 2011;(118):5178-5188.
14. Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA. 2007;(104):13283-13288.
15. Fresquet V, Rieger M, Carolis C, Garcia-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014; (123):4111-4119.